Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Sohei Satoi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6527-5409; OpenAlex author ID A5075713045. Sources: OpenAlex.

Their work

Papers
117 (first author 17, last author 17)
Trials
0
Grants
0
Labs led
1
Collaborators
309
Papers, trials and grants by year

2011: 3 papers · 2012: 4 papers · 2013: 4 papers · 2014: 5 papers · 2015: 5 papers · 2016: 12 papers · 2017: 5 papers · 2018: 2 papers · 2019: 10 papers · 2020: 5 papers · 2021: 8 papers · 2022: 7 papers · 2023: 12 papers · 2024: 4 papers · 2025: 15 papers · 2026: 16 papers

Papers 50 of 117

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Last author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Last author DOI 10.1002/jhbp.70054↗
  3. Survival Impact of Pathological Residual Patterns for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Last author DOI 10.1002/jhbp.70146↗
  4. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  5. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  6. Fecal Bifidobacterium Serves as a Predictor of Postoperative Recurrence After Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1016/j.gastha.2025.100779↗
  7. Long-term outcomes of plastic versus metal stents for preoperative biliary drainage in pancreatic cancer: a nationwide propensity score-matched analysis. Co-author DOI 10.1016/j.gie.2026.05.032↗
  8. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Last author DOI 10.1016/j.hpb.2025.12.001↗
  9. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  10. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  11. Clinical Statistics and Outcomes of Pancreatic Neoplasms in Japan: A Retrospective Cohort Study Using the Japan Pancreatic Cancer Registry. Co-author DOI 10.1097/mpa.0000000000002694↗
  12. Multi-hole Versus Fully Covered Self-expandable Metal Stents for Distal Biliary Obstruction in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002722↗
  13. Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP0… Co-author DOI 10.1097/sla.0000000000006730↗
  14. Mesenteric Versus Conventional Approach During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma (MAPLE-PD trial): A Multicenter Randomized Controlled… Co-author DOI 10.1097/sla.0000000000006900↗
  15. Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer: A Nationwide Study by the Japanese Societ… First author DOI 10.1097/sla.0000000000007012↗
  16. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  17. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Last author DOI 10.1002/ags3.70001↗
  18. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  19. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  20. Long-term outcomes of prophylactic right-half dissection of the superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic ductal adenocar… Co-author DOI 10.1007/s00595-025-03062-6↗
  21. Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia. Co-author DOI 10.1016/j.esmogo.2025.100158↗
  22. Author's reply to the Letter to Editor regarding "Exploring the Role of Neoadjuvant Therapy for Resectable Pancreatic Cancer". Last author DOI 10.1016/j.pan.2024.11.017↗
  23. Clinical importance of suspicious for malignancy compared to positive for malignancy in peritoneal cytology for surgically resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2025.05.006↗
  24. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  25. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design. Co-author DOI 10.1080/14796694.2025.2469467↗
  26. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  27. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  28. Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal… First author DOI 10.1245/s10434-024-16361-y↗
  29. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  30. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Last author DOI 10.1245/s10434-025-18084-0↗
  31. A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Tri… Co-author DOI 10.1371/journal.pone.0325667↗
  32. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Co-author DOI 10.1001/jamanetworkopen.2024.17625↗
  33. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clini… Last author DOI 10.1016/j.pan.2024.03.012↗
  34. Impact of endoscopic ultrasound-guided tissue acquisition on prognosis and peritoneal lavage cytology in resectable or borderline resectable pancreatic ductal … Co-author DOI 10.1016/j.pan.2024.06.001↗
  35. Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib. Last author DOI 10.1186/s40792-024-01975-x↗
  36. Reevaluation of regional lymph nodes in patients with pancreatic ductal adenocarcinoma in the pancreatic body and tail. Co-author DOI 10.1002/ags3.12608↗
  37. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  38. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Soc… Co-author DOI 10.1002/cncr.34580↗
  39. Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancre… Co-author DOI 10.1002/jhbp.1353↗
  40. Standard versus delayed initiation of S-1 adjuvant chemotherapy after surgery for pancreatic cancer: a secondary analysis of a nationwide cohort by the Japan P… Co-author DOI 10.1007/s00535-023-01988-7↗
  41. Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal aden… Co-author DOI 10.1016/j.pan.2022.11.012↗
  42. Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.04.001↗
  43. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  44. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… First author DOI 10.1016/j.pan.2023.07.005↗
  45. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospectiv… Co-author DOI 10.21037/jgo-23-655↗
  46. Autophagy Inhibition Increased Sensitivity of Pancreatic Cancer Cells to Carbon Ion Radiotherapy. Co-author DOI 10.33594/000000639↗
  47. A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.3390/jcm12103477↗
  48. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. First author DOI 10.1002/jhbp.1026↗
  49. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). Co-author DOI 10.1002/jhbp.1049↗
  50. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗

Closest collaborators

The 25 strongest of 309 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daisuke Hashimoto · 32 shared papers, 2021–2026 · strength 5.89
  2. So Yamaki · 47 shared papers, 2011–2026 · strength 5.84
  3. Tomohisa Yamamoto · 47 shared papers, 2011–2025 · strength 4.41
  4. Michiaki Unno · 36 shared papers, 2011–2026 · strength 4.39
  5. Tsutomu Fujii · 26 shared papers, 2016–2026 · strength 3.61
  6. Masayuki Sho · 34 shared papers, 2013–2026 · strength 3.15
  7. Satoshi Hirano · 17 shared papers, 2013–2026 · strength 2.67
  8. Hiroki Yamaue · 31 shared papers, 2013–2026 · strength 2.63
  9. Mitsugu Sekimoto · 17 shared papers, 2020–2025 · strength 2.48
  10. Masamichi Mizuma · 17 shared papers, 2015–2026 · strength 2.41
  11. Ippei Matsumoto · 24 shared papers, 2014–2026 · strength 2.25
  12. Suguru Yamada · 14 shared papers, 2017–2026 · strength 2.23
  13. Tsukasa Ikeura · 13 shared papers, 2013–2026 · strength 2.22
  14. Kenichiro Uemura · 20 shared papers, 2015–2026 · strength 2.22
  15. Fuyuhiko Motoi · 24 shared papers, 2011–2026 · strength 2.21
  16. Yoshifumi Takeyama · 11 shared papers, 2023–2026 · strength 2.00
  17. Hiroaki Yanagimoto · 34 shared papers, 2011–2021 · strength 1.79
  18. Goro Honda · 20 shared papers, 2014–2026 · strength 1.76
  19. Yoshiaki Murakami · 21 shared papers, 2014–2026 · strength 1.68
  20. Satoshi Hirooka · 23 shared papers, 2011–2023 · strength 1.65
  21. Yuki Matsui · 8 shared papers, 2022–2026 · strength 1.63
  22. Manabu Kawai · 17 shared papers, 2014–2026 · strength 1.62
  23. Yuichi Nagakawa · 10 shared papers, 2018–2026 · strength 1.46
  24. Itaru Endo · 9 shared papers, 2019–2026 · strength 1.41
  25. Atsushi Masamune · 9 shared papers, 2016–2026 · strength 1.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.